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N2O anesthesia may
exacerbate
hyperhomocysteinemia and
endothelial dysfunction in
patients with renal impairment
To the Editor: Patients with renal impairment have el-
evated homocysteine levels and are at high risk of car-
diovascular complications [1]. Herein, we caution against
the use of nitrous oxide (N2O) anesthesia for these
patients.
Under most conditions, N2O appears to be inert,
but prolonged exposure to the gas leads to significant
increases in plasma homocysteine levels in patients pre-
senting for elective craniotomy [2]. N2O directly inhibits
methionine synthase, which contains cobalamin as a pros-
thetic group and catalyzes a folate-dependent conversion
of homocysteine to methionine. Recently, Selzer et al [3]
have described the neurologic deterioration and death of
a child anesthetized twice with N2O before the diagnosis
of 5,10-methylenetetrahydrofolate reductase (MTHFR)
deficiency was established. The N2O-induced defect of
methionine synthase superimposed on an inherited de-
fect of MTHFR caused the death of the reported patient.
The adverse effects of N2O were reported in two other
children with severe dietary cobalamin deficiency. One
developed acute neurologic deficit six days after N2O
anesthesia, and the other showed hypotonia, dehydra-
tion, and acidosis three weeks after N2O anesthesia.
Acute rise in plasma homocysteine level causes sub-
stantial impairment of endothelial function in healthy
volunteers [4]. It is likely that when such endothelial dys-
function occurs in patients with renal impairment, it exac-
erbates the vascular dysfunction. The above-mentioned
catastrophic events may provide us a cautionary mes-
sage; plasma homocysteine and methionine levels should
be closely monitored in patients with renal impairment
undergoing N2O anesthesia. Pretreatment with vita-
mins (folic acid, vitamin B6, and B12) may block the
N2O-induced increase in homocysteine level in at-risk
individuals.
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Failure to follow K/DOQI
guidelines decreases
effectiveness of access
flow surveillance
To the Editor: The major drawback of the recent
study on graft surveillance [1] is its failure to use major
Kidney Disease Outcome Quality Initiative (K/DOQI)
guidelines.
The K/DOQI Qa guideline (25% flow drop over
4 months, or a drop >20% within 1 month in the 1999
version) was not applied. Flow trends are considered to
be more predictive of thrombosis than a single flow mea-
surement (Qa). The authors argue that the application of
the Qa criterion would not have altered the study out-
come based on their previous study [2]. First, their pre-
vious study did not use interventions. Second, the results
of that study have been disputed because of an incor-
rect statistic approach and multiple errors in calculations
[3, 4]. Furthermore, when this study was analyzed by oth-
ers [3, 4], it was shown to actually support the K/DOQI
guidelines. Failure to apply both K/DOQI thresholds re-
sulted in decreased preemptive percutaneous translumi-
nal angioplasty (PTA) rate to 0.34/patient-years versus
0.54/patient-years in a study in which both flow thresholds
were used [5], suggesting the patient’s undertreatment.
Qa should be measured during the first 11/2 hour
of hemodialysis (K/DOQI). The hemodynamic uncer-
tainties related to patient status late in the treatment
(15 minutes before the end, according to the authors’ pro-
tocol) could impact flow results significantly. This brings
into question all access flow data.
The authors’ noncompliance with the K/DOQI guide-
lines decreased the quality of their clinical outcomes.
Their article sends a misleading message to the
hemodialysis community about the effectiveness of flow
surveillance.
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